A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT02737332
Last Updated: 2021-11-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
53 participants
INTERVENTIONAL
2016-03-21
2017-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zytiga® (Abiraterone Acetate)
1,000 MG (4 x 250 mg qd)
Zytiga® (Abiraterone Acetate)
Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
SoluMatrix™ (Abiraterone Acetate)
500 mg (4 x 125 mg qd)
SoluMatrix™ (Abiraterone Acetate)
SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zytiga® (Abiraterone Acetate)
Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
SoluMatrix™ (Abiraterone Acetate)
SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male subjects at least 18 years of age or older at time of consent
3. Pathologically confirmed adenocarcinoma of the prostate
4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level \<50 ng/dL at screening
5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study medication will be accepted.
6. Meeting disease progression according to the recommendations of the prostate cancer working group 2 by one of the following criteria:
* Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 2 ng/mL,
* Imaging progression (CT/MRI) by RECIST criteria
* Nuclear scan progression by new lesion.
7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks prior to the start of study medication; discontinuation of bicalutamide at least 6 weeks prior to start of study medication.
8. Discontinuation of Radiotherapy \> 4 weeks prior to start of study medication.
9. ECOG performance status of 0-1 at screening
10. Screening blood counts of the following:
* Absolute neutrophil count \> 1500/µL
* Platelets \> 100,000/µL
* Hemoglobin \> 9 g/dL
11. Screening chemistry values of the following:
* ALT and AST \< 2.5 x ULN
* Total bilirubin \< 1.5 x ULN
* Creatinine\< 1.5 x ULN
* Albumin \> 3.0 g/dL
12. Potassium \> 3.5 mmol/L
13. Life expectancy of at least 6 months at screening
14. Subject is willing and able to comply with all protocol requirements assessments
15. Agrees to protocol-defined use of effective contraception.
Exclusion Criteria
2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17 inhibitor
3. Prior therapy with enzalutamide
4. Prior use of experimental androgen receptor antagonist
5. Previous exposure to Ra-223:Xofigo
6. Previous chemotherapy
7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study medication. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug are eligible.
8. Therapy with estrogen within 30 days prior to the start of study medication
9. Use of systemic glucocorticoids equivalent to \> 10 mg of prednisone daily; patients who have discontinued or have reduced dose to \< 10 mg prednisone within 14 days prior to the start of study medication will be eligible
10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto) within 30 days of start of study medication
11. Known metastases to the brain or CNS involvement
12. History of other malignancy within the previous 2 years
13. Major surgery within 30 days prior to the start of study medication
14. Blood transfusion within 30 days of screening
15. Serious, persistent infection within 14 days of the start of study medication
16. Persistent pain that requires the use of a narcotic analgesic
17. Known gastrointestinal disease or condition that may impair absorption
18. Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.
19. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
20. Have poorly controlled diabetes.
21. Uncontrolled hypertension
22. History of New York Heart Association (NYHA) class III or IV heart failure
23. Serious concurrent illness, including psychiatric illness, that would interfere with study participation
24. Inability to swallow tablets whole
25. Known hypersensitivity to any excipients in study medications
26. Moderate to severe hepatic impairment (Child-Pugh Classes B and C)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Pharmaceutical Industries Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Nemeth, PhD
Role: STUDY_DIRECTOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alliance Research
Laguna Hills, California, United States
Tower Urology
Los Angeles, California, United States
San Bernardino Urological
San Bernardino, California, United States
Skyline Urology
Torrance, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Urology Associates, P.C.
Englewood, Colorado, United States
Manatee Medical Research
Bradenton, Florida, United States
North Idaho Urology
Coeur d'Alene, Idaho, United States
The Iowa Clinic
West Des Moines, Iowa, United States
Wichita Urology Group
Wichita, Kansas, United States
Chesapeake Urology Research Associates
Towson, Maryland, United States
Lincoln Urology, PC
Lincoln, Nebraska, United States
Urology Cancer Center
Omaha, Nebraska, United States
Brooklyn Urology Research Group
Brooklyn, New York, United States
Associated Urologist of North Carolina
Raleigh, North Carolina, United States
Urology Clinics of North Texas
Dallas, Texas, United States
Urology of Virginia
Virginia Beach, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHL-AA-201
Identifier Type: -
Identifier Source: org_study_id